Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NSE /
  3. SPARC.NSE

Sun Pharma Advanced Research Company Limited (SPARC NSE) stock market data APIs

INR229 2.34(1%) as of July 26, 2024
Price chart is built with Anychart

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Sun Pharma Advanced Research Company Limited Financial Data Overview

226.66
229
-
232
225.5
196.1-472.8
75 495 M
325 M
755 M
-3.07
0.86
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'SPARC',
Type: 'Common Stock',
Name: 'Sun Pharma Advanced Research Company Limited',
Exchange: 'NSE',
CurrencyCode: 'INR',
CurrencyName: 'Indian Rupee',
CurrencySymbol: 'INR',
CountryName: 'India',
CountryISO: 'IN',
OpenFigi: NULL,
ISIN: 'INE232I01014',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'March',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - Specialty & Generic',
}

Sun Pharma Advanced Research Company Limited Fundamental Data is available in our Financial Data APIs

  • Net Revenue 755 M
  • EBITDA -4 023 384 064
  • Earnings Per Share -11.8
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Sun Pharma Advanced Research Company Limited Earnings via APIs

  • Latest Release 2024-02-05
  • EPS/Forecast 10

Get Sun Pharma Advanced Research Company Limited End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Sun Pharma Advanced Research Company Limited latest news via APIs

OneThree Biotech Joins Forces with SPARC to Characterize a Key Oncologic Pathway

AI-driven collaboration aims to facilitate discovery and development of innovative compounds and combination therapies in precision oncology NEW YORK, June 8, 2021 /PRNewswire/ -- OneThree Biotech to...
  • ARTIFICIAL INTELLIGENCE
  • BIOLOGICAL MECHANISMS
  • BIOTECH
  • COMBINATION THERAPIES
  • DRUG DISCOVERY
  • ONCOLOGY RESEARCH
  • PRECISION ONCOLOGY
  • SPARC
  • SUN PHARMA ADVANCED RESEARCH COMPANY LTD

OneThree Biotech Joins Forces with SPARC to Characterize a Key Oncologic Pathway

AI-driven collaboration aims to facilitate discovery and development of innovative compounds and combination therapies in precision oncology NEW YORK, June 8, 2021 /PRNewswire/ -- OneThree Biotech to...
  • ARTIFICIAL INTELLIGENCE
  • BIOLOGICAL MECHANISMS
  • BIOTECH
  • COMBINATION THERAPIES
  • DRUG DISCOVERY
  • ONCOLOGY RESEARCH
  • PRECISION ONCOLOGY
  • SPARC
  • SUN PHARMA ADVANCED RESEARCH COMPANY LTD
Do you have any questions?
support@eodhistoricaldata.com